Publicación:
Diagnóstico de cáncer de próstata posterior a tratamiento antibiótico en pacientes con antígeno prostático específico entre 4 y 10 ng/ml

Vista sencilla de ítem
dc.contributor.authorInfantes Burgos, Ronald Javierspa
dc.contributor.authorMaciá Carrasquilla, Juan Alonsospa
dc.contributor.authorRamos Clason, Enrique Carlosspa
dc.date.accessioned2014-01-15 00:00:00
dc.date.available2014-01-15 00:00:00
dc.date.issued2014-01-15
dc.format.mimetypeapplication/pdfspa
dc.identifier.doi10.32997/rcb-2014-2885
dc.identifier.eissn2389-7252
dc.identifier.issn2215-7840
dc.identifier.urihttps://hdl.handle.net/11227/13104
dc.identifier.urlhttps://doi.org/10.32997/rcb-2014-2885
dc.language.isospaspa
dc.publisherUniversidad de Cartagenaspa
dc.relation.bitstreamhttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/2885/2428
dc.relation.citationeditionNúm. 1 , Año 2014spa
dc.relation.citationendpage40
dc.relation.citationissue1spa
dc.relation.citationstartpage35
dc.relation.citationvolume5spa
dc.relation.ispartofjournalRevista Ciencias Biomédicasspa
dc.relation.referencesOesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145(5):907-923.spa
dc.relation.referencesCatalona WJ, Ramos CG, Carvalhal GF, Yan Y. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology. 2000;55(6):791-795.spa
dc.relation.referencesGilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting PSA cut point of 2.5 ng/Ml for prompting prostate biopsy: review of 36,316 biopsies. Urology. 2005;65(3):549-553.spa
dc.relation.referencesNadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995;154(2):407-413.spa
dc.relation.referencesCarver BS, Bozeman CB, Williams BJ, Venable DD. The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen. J Urol. 2003;169(2):589-591.spa
dc.relation.referencesKarazanashvili G, Managadze L. Prostate-specificanti gen (PSA) value change after antibacterial therapy of prostate inflammation, as a diagnostic method for prostate cancer screening in cases of PSA value within 4–10 ng/ml and nonsuspicious results of digital rectal examination. Eur Urol. 2001;39:538-543.spa
dc.relation.referencesStancik I, Luftenegger W, Klimpfinger M. Muller MM, Hoeltl W. Effect of NIH-IV prostatitis on free and free-to-total PSA. Eur Urol. 2004;46(6)760-764.spa
dc.relation.referencesKrieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA.1999;282(3):236-246.spa
dc.relation.referencesSchaeffer AJ, Wu SC, Tennenberg AM, Kahn JB. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol. 2005;174(1):161-164.spa
dc.relation.referencesSheikh M, Al-Saeed O, Kehinde EO, Sinan T, Anim JT, Ali Y. Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab men. Int Urol Nephrol. 2005;37(4):721-726.spa
dc.relation.referencesYaman O, Gogus C, Tulunay O, et al. Increased prostate-specific antigen in subclínical prostatitis: the role of aggressiveness and extension of inflammation. Urol Int. 2003;71:160-164.spa
dc.relation.referencesOzden C, Inal G, Adsan O, Yazici S, Ozturk B, Cetinkaya M. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA. Urol Int. 2003;71(2):150-153.spa
dc.relation.referencesOkada K, Kojima M, Naya Y, Kamoi K, Yokoyama K, Takamatsu T, Miki T. Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology. 2000;55(6):892-898.spa
dc.relation.referencesGümüş BH, Neşe N, Gündüz MI, Kandiloglu AR, Ceylan Y, Büyüksu C. Does asymptomatic inflammation increase PSA? A histopathological study comparing benign and malignant tissue biopsy specimens. Int Urol Nephrol. 2004;36(4):549-553.spa
dc.relation.referencesKobayashi M, Nukui A, Morita T. Serum PSA and percent free PSA value changes after antibiotic treatment. A diagnostic method in prostate cancer suspects with asymptomatic prostatitis. Urol Int. 2008;80(2):186-192.spa
dc.relation.referencesKim YJ, Kim SO, Ryu KH, Hwang IS, Hwang EC, Oh KJ, et al. Prostate cancer can be detected even in patients with decreased PSA less than 2.5 ng/ml after treatment of chronic prostatitis. Korean J Urol. 2011;52(7):457-460.spa
dc.relation.referencesTang P, Xie KJ, Wang B, Deng XR, Ou RB. Antibacterial therapy improves the effectiveness of prostate cancer detection using prostate-specific antigen in patients with asymptomatic prostatitis. Int Urol Nephrol. 2010;42(1):13–18.spa
dc.relation.referencesCatalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997;277(18):1452-1455.spa
dc.relation.referencesCatalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279(19):1542-1547.spa
dc.relation.referencesLodding P, Aus G, Bergdahl S, Frösing R, Lilja H, Pihl CG, Hugosson J. Characteristics of screening detected Prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen. J Urol. 1998;159(3):899-903.spa
dc.relation.referencesDjavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol. 2000;163(4):1144-1149.spa
dc.relation.referencesBabaian RJ. Extended field prostate biopsy enhances cancer detection. Urology. 2000;55(4):453-456.spa
dc.relation.referencesBabaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HA. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng./ml: relation to biopsy strategy. J Urol. 2001;165:757-760.spa
dc.rightsRevista Ciencias Biomédicas - 2020spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/spa
dc.sourcehttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/2885spa
dc.subjectNeoplasias de la próstataspa
dc.subjectAntígeno prostático específicospa
dc.subjectPróstata.spa
dc.titleDiagnóstico de cáncer de próstata posterior a tratamiento antibiótico en pacientes con antígeno prostático específico entre 4 y 10 ng/mlspa
dc.title.translatedDiagnóstico de cáncer de próstata posterior a tratamiento antibiótico en pacientes con antígeno prostático específico entre 4 y 10 ng/mleng
dc.typeArtículo de revistaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.localJournal articleeng
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dspace.entity.typePublication

Archivos

Colecciones

Revista Ciencias Biomédicas - Portal de Revistas

Datos de Contacto

Imagen Escudo Universidad de Cartagena

 

 

 

Sede: Claustro de San Agustín, Centro Histórico, Calle de la Universidad Cra. 6 #36-100
Colombia, Bolívar, Cartagena
Ver más...

Línea de Atención

Línea Anticorrupción

Síguenos en: